Aliskiren Hemifumarate , ≥98% , 173334-58-2

Synonym(s):
(2S,4S,5S,7S)-N-(2-Carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]-octanamide hemifumarate;CGP-60536;CGP60536B;Rasilez;SPP-100

CAS NO.：173334-58-2

Empirical Formula: C30H53N3O6

Molecular Weight: 551.758

MDL number: MFCD10566724

EINECS: 630-415-8

PRODUCT Properties

• Melting point: 72-75?C
• storage temp.: Sealed in dry,Store in freezer, under -20°C
• solubility: Methanol (Slightly), Water (Slightly)
• form: Solid
• color: White

Description and Uses

Aliskiren hemifumarate (Tekturna(R)) was the first renin inhibitor approved by FDA in March 2007, and genomic analysis validated that Pgx-based dosing guidelines are not required for this drug. The once-daily, oral, direct renin inhibitor received FDA approval for treatment of high blood pressure as mono therapy or in combination with other antihypertensive medications. Furthermore, aliskiren demonstrated increased efficacy when used in combination with other commonly used blood pressure-lowering medications. Novartis is conducting a large outcome trial program to evaluate the long-term effects of aliskiren and of direct renin inhibition in general.

An orally active, synthetic nonpeptide renin inhibitor. Antihypertensive.

Safety

• Symbol(GHS): GHS08,GHS07
• Signal word: Danger
• Hazard statements: H360-H335-H315-H319
• Precautionary statements: P264-P280-P302+P352-P321-P332+P313-P362-P264-P280-P305+P351+P338-P337+P313P